

Date: 18.06.2020

To,  
The Secretary,  
The B.S.E Limited  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai - 400 001



Sub: Submission of Audited Standalone and Consolidated Financial Results of the Company along with Auditor's Report as per Provisions of Regulation 33 of SEBI (LODR) Regulations, 2015.

Please find enclosed here with the following Documents in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015:

1. Financial Results: Audited Standalone and Consolidated Financial Results along with Auditor's Report of the company for the Fourth Quarter/ Year Ended 31<sup>st</sup> March, 2020.

This is for your Information and Necessary Records.

Thanking you  
For **TRIMURTHI LIMITED**



**Arun Kumar Bhangadia**  
Managing Director  
DIN: 00021024

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956

Date: 18.06.2020

To,  
The Secretary,  
The B.S.E Limited  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai- 400 001

Sub: Outcome of the Board Meeting held on 18/06/2020 as per Regulation 30, 33 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

The Board of Directors of the Company at its meeting held today, Thursday, the 18<sup>th</sup> Day of June, 2020 at Registered Office, have approved and taken on record the following:

1. The Board has considered and approved the minutes of the previous board meeting.
2. The Board has considered and approved the Audited Standalone and Consolidated Financial Results along with Auditor's Report issued by the Statutory Auditors of the Company for the Quarter IV/Year ended 31<sup>st</sup> March, 2020 in compliance with Indian Accounting Standards (Ind-AS), SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013.
3. The board has considered and approved venturing into the business of manufacture of Gloves, Masks and other surgical and medical consumables other Textile related products, non woven Fabric cloth, etc., in partnership.


There being no other matter meeting of the Board of Directors concluded with the vote of thanks.

The Meeting of the Board of Directors of the company commenced at 03.30 P.M. and Concluded at 04:30 P.M.

Request you to take same on records.

Thanking you

For **TRIMURTHI LIMITED**

  
**Arun Kumar Bhangadia**  
Managing Director  
DIN: 00021024

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956



**TRIMURTHI LIMITED**  
**Standalone Statement of Assets and Liabilities**



**TRIMURTHI**  
GROUP

(Amount in Lakhs)		
Particulars	Year Ended 31-03-2020	Year Ended 31-03-2019
<b>ASSETS</b>		
<b>1 Non Current Assets</b>		
a Property, Plant and Equipments	30.82	36.86
b Capital Work In Progress	-	-
c Investment Prpoerty	-	-
d Goodwill	-	-
e Other Intangible Assets	-	-
f Intangible Assets under development	0.08	0.37
g Biological assets other than bearer plants	-	-
h Financial Assets:	-	-
Investments	-	-
Trade Receivables	352.68	272.16
Loans	-	-
Others	-	-
Loans	-	-
Others	-	-
i Deferred Tax Assets (net)	-	-
Other Non Current Assets	20.00	20.75
<b>Total Non Current Assets</b>	<b>403.58</b>	<b>330.14</b>
<b>2 Current Assets</b>		
a Inventories	7.83	10.27
b Financial Assets	-	-
Investments	-	-
Trade Receivables	-	-
Cash and Cash Equivalents	228.32	213.97
Bank balances other than above	95.23	16.03
Loans	-	-
Others	367.98	434.46
c Current Tax Assets (net)	-	-
d Other Current Assets	101.05	208.25
<b>Total Current Assets</b>	<b>800.40</b>	<b>882.98</b>
<b>Total Assets</b>	<b>1,203.98</b>	<b>1,213.12</b>
<b>EQUITY AND LIABILITIES</b>		
<b>1 Equity</b>		
a Equity Share Capital	810.00	810.00
b Other Equity	397.10	391.04
<b>Total - Equity</b>	<b>1,207.10</b>	<b>1,201.04</b>
<b>2 Liabilities</b>		
<b>Non Current Liabilities</b>		
a Financial Liabilities	-	-
Borrowings	-	-
Trade Payables	-	-
Other Financial Liabilities	-	-
b Provisions	-	-
c Deferred Tax Liabilities (net)	(5.85)	(6.38)
d Other Non Current Liabilities	-	-
<b>Total Non Current Liabilities</b>	<b>(5.85)</b>	<b>(6.38)</b>
<b>Current Liabilities</b>		
a Financial Liabilities	-	-
Borrowings	-	-
Trade Payables	-	-
Other Financial Liabilities	0.67	10.38
b Other Current Liabilities	-	-
c Provisions	1.42	3.58
d Currenr Tax Liabilities (net)	-	-
<b>Total Current Liabilities</b>	<b>2.73</b>	<b>18.45</b>
<b>Total - Equity and Liabilities</b>	<b>1,203.98</b>	<b>1,213.12</b>

Place: Hyderabad

Date: 18-06-2020

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956

For Trimurthi Ltd  
Arun Kumar Bhanqadia  
Managing Director  
Din No. 00021024



**TRIMURTHI LIMITED**  
4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500095,  
STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS  
FOR THE QUARTER IV AND 12 MONTHS ENDED 31ST MARCH 2020

(Amount in lakhs except EPS)

PARTICULARS	QUARTER ENDED			YEAR ENDED	
	31.03.2020 (AUDITED)	31.12.2019 (UNAUDITED)	31.03.2019 (AUDITED)	31.03.2020 (AUDITED)	31.03.2019 (AUDITED)
<b>1. INCOME</b>					
INCOME FROM OPERATIONS	51.03	18.34	48.84	103.23	359.19
OTHER INCOME	10.41	11.90	11.14	47.31	13.23
<b>TOTAL INCOME</b>	<b>61.44</b>	<b>30.24</b>	<b>59.98</b>	<b>150.54</b>	<b>372.43</b>
<b>2. EXPENSES</b>					
PURCHASES					
COST OF MATERIALS CONSUMED	24.81	12.94	26.74	73.21	277.05
MANUFACTURING EXPENSES					
WORK IN PROGRESS AND STOCK IN TRADE					
RENT	(1.13)	3.91	0.17	2.44	0.03
EMPLOYEE BENEFITS EXPENSE	1.05	0.30	0.75	1.95	3.00
FINANCE COSTS	6.90	8.57	8.07	28.30	32.72
DEPRECIATION AND AMORTISATION EXPENSES	-	-	-	-	-
OTHER EXPENSES	0.92	2.26	3.34	7.82	12.15
<b>TOTAL EXPENSES</b>	<b>41.79</b>	<b>31.67</b>	<b>45.77</b>	<b>139.89</b>	<b>353.34</b>
<b>3. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE EXCEPTIONAL ITEMS (1-2)</b>	<b>19.65</b>	<b>(1.42)</b>	<b>14.21</b>	<b>10.65</b>	<b>19.08</b>
<b>4. EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS</b>					
<b>5. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (3-4)</b>	<b>19.65</b>	<b>(1.42)</b>	<b>14.21</b>	<b>10.65</b>	<b>19.08</b>
<b>6. TAX EXPENSES</b>					
-CURRENT TAX	1.11	0.01	3.52	1.17	(5.92)
-TAX ADJUSTMENTS RELATING TO EARLIER YEARS	0.64	-	3.78	0.64	4.49
-DEFERRED TAX (NET)	0.47	0.01	(0.26)	0.53	(10.40)
<b>7. NET PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (5-6)</b>	<b>18.55</b>	<b>(1.43)</b>	<b>10.69</b>	<b>9.48</b>	<b>25.00</b>
<b>8. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS</b>					
<b>9. TAX EXPENSES FOR DISCONTINUED OPERATIONS</b>					
<b>10. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (8-9)</b>					
<b>11. PROFIT/(LOSS) FOR THE PERIOD (7+10)</b>	<b>18.55</b>	<b>(1.43)</b>	<b>10.69</b>	<b>9.48</b>	<b>25.00</b>
<b>12. OTHER COMPREHENSIVE INCOME</b>					
A. (i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS					
(ii) INCOME TAX RELATING TO ITEM THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS					
B. (i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS	(2.01)	(0.19)	3.92	(3.43)	(6.20)
(ii) INCOME TAX RELATING TO ITEM THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS					
<b>13. TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (11+12) (COMPRISING PROFIT (LOSS) AND OTHER COMPREHENSIVE INCOME)</b>	<b>16.54</b>	<b>(1.62)</b>	<b>14.61</b>	<b>6.05</b>	<b>18.80</b>
<b>14. EARNINGS PER EQUITY SHARE (FOR CONTINUING OPERATION) :</b>					
(i) BASIC	0.23	(0.02)	0.13	0.12	0.31
(ii) DILUTED	0.23	(0.02)	0.13	0.12	0.31
<b>15. EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATION) :</b>					
(i) BASIC					
(ii) DILUTED					
<b>16. EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATION) :</b>					
(i) BASIC	0.23	(0.02)	0.13	0.12	0.31
(ii) DILUTED	0.23	(0.02)	0.13	0.12	0.31

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956







**TRIMURTHI**  
GROUP

**TRIMURTHI LIMITED**

SCHEDULE III OF THE COMPANIES ACT 2013

**PART-II**

PARTICULARS	QUARTER ENDED			YEAR ENDED	
	31.03.2020 (AUDITED)	31.12.2019 (UNAUDITED)	31.03.2019 (AUDITED)	31.03.2020 (AUDITED)	31.03.2019 (AUDITED)
<b>A PARTICULARS OF SHARE HOLDING</b>					
1. Public Share Holding					
- Number of Shares	2900600	2900600	2900600	2900600	2900600
- Percentage of shareholding	35.81%	35.81%	35.81%	35.81%	35.81%
2. Promoters and promoter group shareholding					
a. Pledged / encumbered					
- No of Equity Shares	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
- Percentage of Shares (of the shareholding of promoter and promoter group)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
- Percentage of Shares (of the total share capital of the company)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
b. Non encumbered					
- No of Equity Shares	5199400	5199400	5199400	5199400	5199400
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.19%	64.19%	64.19%	64.19%	64.19%

Particulars	3 Months Ended ( 31/03/2020)
<b>B Investor Complaints</b>	
Pending at the beginning of the quarter	-NIL-
Received during the quarter	-NIL-
Disposed during the quarter	-NIL-
Remaining unsolved during the quarter	-NIL-

**TRIMURTHI LIMITED**

**Segment Reporting**

PARTICULARS	QUARTER ENDED			YEAR ENDED	
	31.03.2020 (AUDITED)	31.12.2019 (UNAUDITED)	31.03.2019 (AUDITED)	31.03.2020 (AUDITED)	31.03.2019 (AUDITED)
<b>1. Segment Revenue</b>					
a. Pharma Business	-	-	-	-	-
b. Financial Services	10.67	10.80	12.70	42.56	57.64
c. Investments	(0.48)	1.10	11.14	4.53	12.99
d. Trading in Shares	51.25	18.34	9.97	103.45	30.81
e. Foods	-	-	26.17	-	270.99
<b>Total</b>	<b>61.44</b>	<b>30.24</b>	<b>59.97</b>	<b>150.54</b>	<b>372.43</b>
Less: Inter Segment Revenue	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Net Sales/ Income From Operations</b>	<b>61.44</b>	<b>30.24</b>	<b>59.97</b>	<b>150.54</b>	<b>372.43</b>
<b>2. Segment Profits ( Before tax &amp; Interest From Each Segment)</b>					
a. Pharma Business	-	-	-	-	-
b. Financial Services	10.67	10.80	8.78	42.56	45.45
c. Investments	(0.48)	1.10	11.14	4.53	12.99
d. Trading in Shares	9.46	(13.32)	4.81	(36.44)	13.97
e. Foods	-	-	(10.51)	-	(53.33)
<b>Total</b>	<b>19.65</b>	<b>(1.42)</b>	<b>14.21</b>	<b>10.65</b>	<b>19.08</b>
Less:					
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Total Profit Before Tax</b>	<b>19.65</b>	<b>(1.42)</b>	<b>14.21</b>	<b>10.65</b>	<b>19.08</b>
<b>3. Capital Employed</b>					
a. Pharma Business	29.50	29.50	-	29.50	-
b. Financial Services	367.98	369.90	544.22	367.98	544.22
c. Investments	23.18	30.19	272.16	23.18	272.16
d. Trading in Shares	486.44	460.97	372.38	486.44	372.38
e. Foods	300.00	300.00	12.29	300.00	12.29
<b>Total</b>	<b>1,207.10</b>	<b>1,190.56</b>	<b>1,201.04</b>	<b>1,207.10</b>	<b>1,201.04</b>

**Notes:**

- 1 Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- 2 The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on 18-06-2020
- 3 The above standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34- Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.

Place: Hyderabad  
Date: 18-06-2020

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956





**TRIMURTHI LIMITED**  
Consolidated Statement of Assets and Liabilities

Particulars	(Amount in Lakhs)	
	Year Ended 31-03-2020	Year Ended 31-03-2019
<b>ASSETS</b>		
<b>1 Non Current Assets</b>		
a Property, Plant and Equipments	177.69	188.66
b Capital Work In Progress	-	-
c Investment Prpoerty	-	-
d Goodwill	-	-
e Other Intangible Assets	-	-
f Intangible Assets under development	5.50	3.09
g Biological assets other than bearer plants	-	-
h Financial Assets:	-	-
Investments	-	-
Trade Receivables	29.66	49.14
Loans	-	-
Others	-	-
Loans	-	-
Others	-	-
i Deferred Tax Assets (net)	-	-
Other Non Current Assets	-	-
	20.15	21.06
<b>Total Non Current Assets</b>	<b>233.00</b>	<b>261.95</b>
<b>2 Current Assets</b>		
a Inventories	-	-
b Financial Assets	90.68	79.40
Investments	-	-
Trade Receivables	-	-
Cash and Cash Equivalents	351.34	328.73
Bank balances other than above	111.78	19.93
Loans	-	-
Others	445.00	424.23
c Current Tax Assets (net)	140.40	-
d Other Current Assets	-	-
	-	219.78
<b>Total Current Assets</b>	<b>1,139.21</b>	<b>1,072.07</b>
<b>Total Assets</b>	<b>1,372.21</b>	<b>1,334.02</b>
<b>EQUITY AND LIABILITIES</b>		
<b>1 Equity</b>		
a Equity Share Capital	-	-
b Other Equity	810.00	810.00
<b>Total - Equity</b>	250.29	282.05
	<b>1,060.29</b>	<b>1,092.05</b>
<b>Non Controlling Interest</b>	<b>52.48</b>	<b>50.05</b>
<b>2 Liabilities</b>		
<b>Non Current Liabilities</b>		
a Financial Liabilities	-	-
Borrowings	-	-
Trade Payables	76.72	93.07
Other Financial Liabilities	-	-
b Provisions	-	-
c Deferred Tax Liabilities (net)	-	-
d Other Non Current Liabilities	1.90	0.23
	-	-
<b>Total Non Current Liabilities</b>	<b>78.62</b>	<b>93.30</b>
<b>Current Liabilities</b>		
a Financial Liabilities	-	-
Borrowings	-	-
Trade Payables	-	-
Other Financial Liabilities	164.81	80.76
b Other Current Liabilities	-	-
c Provisions	13.28	7.35
d Currenr Tax Liabilities (net)	-	-
	2.74	10.51
<b>Total Current Liabilities</b>	<b>180.82</b>	<b>98.62</b>
<b>Total - Equity and Liabilities</b>	<b>1,372.21</b>	<b>1,334.02</b>

Place: Hyderabad  
Date: 18-06-2020

**TRIMURTHI LIMITED**  
(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-731/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956

For Trimurthi Ltd  
Arun Kumar Bhangadia  
Managing Director  
Din No. 00021024



# TRIMURTHI LIMITED

SCHEDULE III OF THE COMPANIES ACT 2013

CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER IV AND 12 MONTHS ENDED 31ST MARCH, 2020




## PART-I

(Amount in lakhs Except EPS)

Particulars	Quarter Ended				
	31-03-2020	31-12-2019	31-03-2019	31-03-2020	31-03-2019
	Audited	Unaudited	Audited	Audited	Audited
<b>I. Income From Operations</b>					
Net Sales / Income from Operations	266.24	252.26	255.39	1024.44	1045.92
Other Income	21.30	14.38	34.93	60.11	37.73
<b>II. Total Income</b>	<b>287.54</b>	<b>266.64</b>	<b>290.32</b>	<b>1084.55</b>	<b>1083.65</b>
<b>III. Expenses</b>					
a. Consumption of Raw Material	(9.27)	154.05	28.81	211.84	154.21
b. Purchase of Traded Goods/Shares	140.81	119.11	146.71	552.25	594.28
c. (Increase)/Decrease in stock in trade and work in Progress	(2.90)	3.30	19.23	(9.45)	1.95
d. Manufacturing Expenses	104.35	(45.92)	36.86	162.05	153.86
e. Employee benefits expense	23.04	24.97	22.95	96.49	98.62
f. Rent	2.25	1.50	1.95	6.75	7.80
g. Finance Cost	2.07	3.01	3.36	11.45	12.97
h. Depreciation	4.01	5.07	5.77	19.14	21.25
i. Other Expenditure	18.66	11.50	10.37	55.52	51.12
<b>Total</b>	<b>283.02</b>	<b>276.60</b>	<b>276.00</b>	<b>1106.04</b>	<b>1096.05</b>
<b>IV. Profit/ (Loss) before Exceptional and Tax (II-III)</b>	<b>4.52</b>	<b>(9.95)</b>	<b>14.32</b>	<b>(21.50)</b>	<b>(12.40)</b>
<b>V. Exceptional Items/Prior Period Items</b>					
<b>VI. Profit/ (Loss) before tax (IV-V)</b>	<b>4.52</b>	<b>(9.95)</b>	<b>14.32</b>	<b>(21.50)</b>	<b>(12.40)</b>
<b>VII. Tax expense:</b>	<b>1.40</b>	<b>0.86</b>	<b>5.42</b>	<b>4.41</b>	<b>2.38</b>
(1) Current tax	0.87	0.65	5.09	2.74	10.51
(2) Deferred tax	0.53	0.21	0.34	1.68	(8.12)
<b>VIII. Net Profit/ (Loss) for the period from continuing operations (VI-VII)</b>	<b>3.12</b>	<b>(10.81)</b>	<b>8.89</b>	<b>(25.91)</b>	<b>(14.79)</b>
<b>IX. Profit/(loss) from discontinued operations</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>
<b>X. Tax expenses of discontinued operations</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>
<b>XI. Profit/(loss) from Discontinued operations (after tax) (IX-X)</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>
<b>XII. Profit/(loss) for the period (VIII+XI)</b>	<b>3.12</b>	<b>(10.81)</b>	<b>8.89</b>	<b>(25.91)</b>	<b>(14.79)</b>
<b>XIII. Other Comprehensive Income</b>					
A. (i) Items that will not be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
B. (i) Items that will be reclassified to profit or loss	(2.01)	(0.19)	9.76	(3.43)	(0.43)
(ii) Income tax relating to items that will be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>XIV. Total Comprehensive Income for the period (XII+XIII) Comprising Profit (Loss) and Other comprehensive Income for the period )</b>	<b>1.11</b>	<b>(11.00)</b>	<b>18.65</b>	<b>(29.34)</b>	<b>(15.21)</b>
<b>XV. Minority Interest</b>	<b>0.28</b>	<b>0.92</b>	<b>3.91</b>	<b>2.43</b>	<b>9.40</b>
<b>XVI. Total Comprehensive Income for the period after Minority Interest (XIV-XV)</b>	<b>0.83</b>	<b>(11.93)</b>	<b>14.74</b>	<b>(31.76)</b>	<b>(24.62)</b>
<b>XVII. Earnings per equity share (for continuing operation):</b>					
(1) Basic	0.04	(0.14)	0.06	(0.35)	(0.30)
(2) Diluted	0.04	(0.14)	0.06	(0.35)	(0.30)
<b>XVIII. Earnings per equity share (for discontinuing operation):</b>					
(1) Basic	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
(2) Diluted	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>XIX. Earnings per equity share (for discontinuing &amp; continuing operation):</b>					
(1) Basic	0.04	(0.14)	0.06	(0.35)	(0.30)
(2) Diluted	0.04	(0.14)	0.06	(0.35)	(0.30)

## TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
 4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
 Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
 Email : info@trimurthidrugs.com  
 Website : www.trimurthidrugs.com  
 CIN No : L67120TG1994PLC018956







Particulars	Quarter Ended			Year Ended	
	31-03-2020	31-12-2019	31-03-2019	31-03-2020	31-03-2019
	Audited	Unaudited	Audited	Audited	Audited
<b>A. Particulars Of Share Holding</b>					
1. Public Share Holding					
- Number of Shares	2900600	2900600	2900600	2900600	2900600
- Percentage of shareholding	35.81%	35.81%	35.18%	35.81%	35.81%
2. Promoters and promoter group shareholding					
a. Pledged / encumbered					
- No of Equity Shares	-Nil-	-Nil-	-Nil-	-Nil-	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	-Nil-	-Nil-	-Nil-	-Nil-	Nil
- Percentage of Shares (of the total share capital of the company)	-Nil-	-Nil-	-Nil-	-Nil-	Nil
b. Non encumbered					
- No of Equity Shares	5199400	5199400	5199400	5199400	5199400
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.19%	64.19%	64.19%	64.19%	64.19%

Particulars	3 Months Ended ( 31/03/2020)
<b>B. Investor Complaints</b>	
Pending at the beginning of the quarter	-NIL-
Received during the quarter	-NIL-
Disposed during the quarter	-NIL-
Remaining unsolved during the quarter	-NIL-

## Segment Reporting

Particulars	Quarter Ended			Year Ended	
	31-03-2020	31-12-2019	31-03-2019	31-03-2020	31-03-2019
	Audited	Unaudited	Audited	Audited	Audited
1. Segment Revenue					
a. Pharma Business	259.25	124.46	182.68	663.56	663.56
b. Financial Services	24.43	13.08	12.83	57.78	57.78
c. Investments	7.98	1.23	11.14	12.99	12.99
d. Foods	16.80	109.46	73.69	318.51	318.51
e. Trading in Shares	(21.81)	18.41	9.98	30.81	30.81
<b>Total</b>	<b>286.64</b>	<b>266.64</b>	<b>290.32</b>	<b>1083.65</b>	<b>1083.65</b>
Less: Inter Segment Revenue	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Net Sales/ Income From Operations</b>	<b>286.64</b>	<b>266.64</b>	<b>290.32</b>	<b>1083.65</b>	<b>1083.65</b>
2. Segment Profits ( Before tax & Interest From Each Segment)					
a. Pharma Business	16.67	2.19	5.02	23.20	23.20
b. Financial Services	(0.73)	13.08	5.56	32.62	32.62
c. Investments	7.98	1.23	11.14	12.99	12.99
d. Foods	(69.76)	(13.20)	(12.20)	(95.19)	(95.19)
e. Trading in Shares	59.45	(13.25)	4.81	13.97	13.97
<b>Total</b>	<b>13.62</b>	<b>(9.95)</b>	<b>14.32</b>	<b>(12.40)</b>	<b>(12.40)</b>
Less:					
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Total Profit Before Tax</b>	<b>13.62</b>	<b>(9.95)</b>	<b>14.32</b>	<b>(12.40)</b>	<b>(12.40)</b>
3. Capital Employed					
a. Pharma Business	75.39	74.99	85.41	75.39	85.41
b. Financial Services	367.98	369.90	453.22	367.98	453.22
c. Investments	23.18	30.19	49.14	23.18	49.14
d. Foods	107.31	123.41	190.67	107.31	190.67
e. Trading in Shares	486.44	460.97	313.62	486.44	313.62
<b>Total</b>	<b>1060.29</b>	<b>1059.46</b>	<b>1092.06</b>	<b>1060.29</b>	<b>1092.06</b>

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956







**TRIMURTHI**  
GROUP

**Notes:**

- 1 Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- 2 The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 18-06-2020
- 3 The Standalone Unaudited Financial Results have been prepared and subjected to Limited Review by the Statutory Auditors in accordance with Indian Accounting Standards (Ind-AS) as notified by Ministry of Corporate Affairs; Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III Division II of Companies Act, 2013. The Limited Review was carried out by Statutory Auditors for the Quarter ended 31st March, 2020. The Ind AS Complaint figures for the Corresponding previous Quarter ended 31st March, 2019 have not been subject to review or audit, however the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- 4 The results are also available on the webiste of the Company

Place : Hyderabad

Date : 18-06-2020



**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : [info@trimurthidrugs.com](mailto:info@trimurthidrugs.com)  
Website : [www.trimurthidrugs.com](http://www.trimurthidrugs.com)  
CIN No : L67120TG1994PLC018956



**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.p murali.com

TO  
THE BOARD OF DIRECTORS OF  
TRIMURTHI LIMITED

**Report on the audit of the Standalone Financial Results**

**Opinion:**

We have audited the accompanying standalone quarterly financial results of M/s. Trimurthi Limited for the quarter ended 31st March, 2020 and the year to date results for the period from 01-04-2019 TO 31-03-2020, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended 31st March, 2020 as well as the year to date results for the period from 01-04-2019 to 31-03-2020.

**Basis for Opinion:**

We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.







**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.p murali.com

### **Management's Responsibilities for the Standalone Financial Results**

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

*nee*



**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.p murali.com

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.







**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.p murali.com

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For P. Murali & Co,  
Chartered Accountants,  
FRN No: 007257S

A Krishna Rao  
Partner

M.No:020085

UDIN:20020085AAAAFW5409

Place: Hyderabad  
Date: June 18, 2020



**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

## INDEPENDENT AUDITOR'S REPORT

### THE BOARD OF DIRECTORS OF TRIMURTHILIMITED

#### Report on the audit of the Consolidated Financial Results

We have audited the accompanying Statement of Consolidated Financial Results of M/s Trimurthi ("Holding company") and its subsidiaries (holding company and its subsidiaries together referred to as "the Group") for the quarter ended 31<sup>st</sup> March 2020 and for the period from 01-04-2019 to 31-03-2020 ("the Statement"), being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 31<sup>st</sup> March 2020 and the corresponding period from 01-04-2019 to 31-03-2020, as reported in these financial results have been approved by the holding company's Board of Directors, but have not been subjected to audit/review

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports on separate financial statements/ financial information of subsidiaries, the Statement:

- a. includes the results of the following entity:
  - i) Trimurthi Foods Limited
  - ii) Trimurthi Pharmaceuticals (INDIA), Private Limited.
- b. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and
- c. gives a true and fair view, in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated total comprehensive income (comprising of net profit and other comprehensive income) and other financial information of the Group for the quarter ended 31<sup>st</sup> March 2020 and for the period from 01-04-2019 to 31-03-2020.







**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.p murali.com

#### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group, its associates and jointly controlled entities in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

#### **Management's Responsibilities for the Consolidated Financial Results**

These quarterly financial results as well as the year to date consolidated financial results have been prepared on the basis of the interim financial statements.

The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information of the Group including its associates and jointly controlled entities in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and its associates and jointly controlled entities and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.





## P. MURALI & CO.,

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for assessing the ability of the Group and of its associates and jointly controlled entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for overseeing the financial reporting process of the Group and of its associates and jointly controlled entities.

### Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.





**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and jointly controlled entities to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associates and jointly controlled entities to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.





**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.p murali.com

#### Other Matters

Based on our audit conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co,  
Chartered Accountants,  
FRN No: 007257S

A Krishna Rao  
Partner

M.No:020085

UDIN:20020085AAAAFX2579



Place: Hyderabad  
Date: June 18, 2020



Date: 18.06.2020

To,  
The Secretary,  
The B.S.E Limited  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai- 400 001

Sub: Declaration in respect of Audit Report with an Un-modified opinion for the Financial  
Year ended March 31, 2020


Dear Sir/ Madam,

With Reference to the Subject Cited, whereby we submitted Form A for the Audit Report on the  
Financial Results in accordance with Regulation 33 (3) (d) of the SEBI (Listing Obligation and  
Disclosure Requirements) Regulation, 2015, as applicable on that date.

In addition to the above and pursuant to SEBI Circular No. CIR/CFD/CMD/56/2016 dated  
May 27, 2016; we hereby give a declaration that the Statutory Auditors - M/s. P. Murali & Co.,  
Chartered Accountants, have submitted their Audit Report for the year ended March 31, 2020  
with an Un-modified opinion.

Request you take the same on records.

Thanking you  
For TRIMURTHI LIMITED







  
Arun Kumar Bhangadia  
Managing Director  
DIN: 0002102

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956

**Compliance under Regulation 33 of Securities and Exchange Board Of India (Listing Obligations and Disclosure Requirements) Requirements, 2015**

**FORM A  
Annual Audit Report**

1.	Name of the company	Trimurthi Limited
2.	Annual financial statements for year ended	31 <sup>st</sup> March, 2020 (Board Meeting held on Thursday, 18/06/2020)
3.	Type of Audit observation	Un - Qualified
4.	Frequency of observation	Not Applicable
5.	To be signed by-	
	<b>Managing Director</b>	Arun Kumar Bhangadia, Managing Director (DIN: 00021024)  
	<b>Chief Financial Officer (CFO)</b>	VANI MANDA (PAN No. AMPPV9380F)  
	<b>Statutory Auditor of the Company</b>	M/s. P. Murali & Co. Chartered Accountants FRN: 0072575 A Krishna Rao Partner M. No. 020085  
	<b>Chairman of Audit Committee</b>	Mr. Sagar Rajendera Karwa (DIN: 07535666) 